I am a medical oncologist and scientist focusing on clinical and translational research in pancreatic cancer. My research passion is fueled by the fact that pancreatic cancer patients have a very low life expectancy due to lack of early detection and effective treatments. One of my research interests is to translate preclinical discoveries into clinical settings by designing and conducting hypothesis-driven trials. I am the principal investigator (PI) of several investigator-initiated clinical trials (see below) that were developed based on the promising preclinical discoveries made by my collaborators and colleagues. Moreover, my laboratory has been investigating the therapeutic potentials of various downstream effectors of KRAS, the key genetic oncogenic driver for pancreatic ductal adenocarcinoma.
1) A phase I trial of defactinib plus pembrolizumab and gemcitabine in patients with refractory advance cancers (NCT02546531)
2) A phase I trial of ERK inhibitor (BVD-523) plus nab-paclitaxel and gemcitabine in metastatic pancreatic cancer (NTC02608229)
3) A phase I/II trial of tosedostat with capecitabine in patients with metastatic pancreatic adenocarcinoma (NTC02352831)
4) A phase I trial of MLN8237 with nab-paclitaxel in patients with advanced solid malignancies (NTC01677559)